The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration
Open accessAbstract
Purinergic signalling appears to play important roles in neurodegeneration, neuroprotection and neuroregeneration. Initially there is a brief summary of the background of purinergic signalling, including release of purines and pyrimidines from neural and non-neural cells and their ectoenzymatic degradation, and the current characterisation of P1 (adenosine), and P2X (ion channel) and P2Y (G protein-coupled) nucleotide receptor subtypes. There is also coverage of the localization and roles of purinoceptors in the healthy central nervous system. The focus is then on the roles of purinergic signalling in trauma, ischaemia, stroke and in neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, as well as multiple sclerosis and amyotrophic lateral sclerosis. Neuroprotective mechanisms involving purinergic signalling are considered and its involvement in neuroregeneration, including the role of adult neural stem/progenitor cells. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596 · cited 2×
“ATP released during ischaemic damage activated P2X7 receptors on microglia leading to release of proinflammatory cytokines and activated microglia migrate and exhibit macrophagelike activity via P2Y6 receptors (see Iadecola and Anrather, 2011; Fig.”
Burnstock, G. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06930-3 · Cited by 1,852
Self-citationInflammation and neuroprotection in traumatic brain injury.
Corps, K. N., Roth, T. L., & McGavern, D. B. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3558 · Cited by 853
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488 · cited 3×
“to release copious amounts of superoxide primarily via the increased expression of P2X7 receptors (Parvathenani et al., 2003).”
InfluentialAdenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419 · cited 2×
“Reviews have been published concerned with the roles in neuroprotection of adenosine (Stone, 2005; Chen et al., 2007; Ribeiro, 2008; Williams-Karnesky and Stenzel-Poore, 2009; Gomes et al., 2011) and of ATP (Skaper, 2007, 2011; Peterson et al.”
Production and Release of Neuroprotective Tumor Necrosis Factor by P2X7Receptor-Activated Microglia
Suzuki, T., Hide, I., Ido, K., Kohsaka, S., Inoue, K., & Nakata, Y. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3792-03.2004 · Cited by 394
P2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390 · cited 3×
“Potential benefits of P2X7 receptor antagonism in rodent studies of brain and spinal cord injury and neurodegenerative diseases have been described (Wang et al., 2004; Bartlett et al., 2014; Sperl agh and Illes, 2014).”
Cotrina, M. L., Lin, J. H.-C., López-Garcı́a, J. C., Naus, C. C. G., & Nedergaard, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02835.2000 · Cited by 388
Chen, Y., Wu, H., Wang, S., Koito, H., Li, J., Ye, F., Hoang, J., Escobar, S. S., Gow, A., Arnett, H. A., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2410 · Cited by 346
Activation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293 · cited 2×
“Activation of microglia by Ab requires P2X7 receptor expression and it was suggested that Ab microglia stimulation may open new avenues for the treatment of AD (Sanz et al., 2009).”
McLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
P2X7 receptors mediate ischemic damage to oligodendrocytes
Domercq, M., Perez‐Samartin, A., Aparicio, D., Alberdi, E., Pampliega, O., & Matute, C. (2010) · Glia · doi:10.1002/glia.20958 · Cited by 221
Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease
Ryu, J. K., & McLarnon, J. G. (2008) · NeuroReport · doi:10.1097/wnr.0b013e3283179333 · Cited by 134 · cited 2×
“Block of P2X7 receptor-mediated activity with BBG was shown to be neuroprotective in an animal model of AD (Ryu and McLarnon, 2008).”
D'Ambrosi, N., Finocchi, P., Apolloni, S., Cozzolino, M., Ferri, A., Padovano, V., Pietrini, G., Carrì, M. T., & Volonté, C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901212 · Cited by 131
Apolloni, S., Amadio, S., Montilli, C., Volonte, C., & D'Ambrosi, N. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt259 · Cited by 109
Marcellino, D., Suárez-Boomgaard, D., Sánchez-Reina, M. D., Aguirre, J. A., Yoshitake, T., Yoshitake, S., Hagman, B., Kehr, J., Agnati, L. F., Fuxe, K., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0400-0 · Cited by 97 · cited 1×
“Data has implicated the P2X7 receptor in PD (Jun and Kin, 2004; Marcellino et al., 2010).”
Supersensitivity of P2X7 receptors in cerebrocortical cell cultures after in vitro ischemia
Wirkner, K., Köfalvi, A., Fischer, W., Günther, A., Franke, H., Gröger‐Arndt, H., Nörenberg, W., Madarász, E., Vizi, E. S., Schneider, D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03465.x · Cited by 89
The role of p2x7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases
Coutinho-Silva, R., Morandini, A., & Savio, L. B. (2014) · Biomedical Journal · doi:10.4103/2319-4170.127803 · Cited by 81 · cited 1×
“Recent reviews that discuss purinergic signalling and inflammation are available (Eltzschig et al., 2012; Fiebich et al., 2014; Idzko et al., 2014; Morandini et al., 2014).”
P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis.
Amadio, S., Montilli, C., Magliozzi, R., Bernardi, G., Reynolds, R., & Volonte, C. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp193 · Cited by 73 · cited 2×
“Decreased levels of P2Y12 receptors were observed in proximity to demyelinating lesions in sections of cerebral cortex from postmortem MS brains (Amadio et al., 2010).”
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Self-citationMicroglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot, A.-L., Hua, J., Ulmann, L., & Hirbec, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00233 · Cited by 298
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
The Role of the Phosphorus Atom in Drug Design
Rodriguez, J. B., & Gallo‐Rodriguez, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201800693 · Cited by 267
Metadata
- Authors
- Burnstock, G.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 104
- Pages
- 4-17
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W621842823
- Cited by
- 199
- References
- 20
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.